P78358 (CTG1B_HUMAN) Homo sapiens (Human)
Cancer/testis antigen 1 UniProtKBInterProSTRINGInteractive Modelling
180 aa; Sequence (Fasta) ; (Isoform 2)
Available Structures
19 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of HLA-B*07:02 in complex with an NY-ESO-1 peptide |
Heteromer P01889; P61769; | 100 | ||||
| Crystal structure of the KFJ5 TCR-NY-ESO-1-HLA-B*07:02 complex |
Heteromer A0A0B4J268; A0A5B6; P01889; P61769; | 100 | ||||
| Crystal structure of the KFJ37 TCR-NY-ESO-1-HLA-B*07:02 complex |
Heteromer A0A0B4J1U6; A0A0B4J268; P01889; P61769; | 100 | ||||
| Ca2+ release from the endoplasmic reticulum of NY-ESO-1 specific T cells is modulated by the affini… |
Heteromer P04439; P61769; | 88.89 | ||||
| Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC Reveal Native Diagonal Bin… |
Heteromer P01848; P04439; P61769; | 100 | 8×GOL; 1×MG; 5×SO4; 1×IPA; 1×EPE; | |||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; P04439; P61769; | 100 | ||||
| Directed Evolution of Human T-cell Receptor CDR2 residues by phage display dramatically enhances af… |
Heteromer P01848; P04439; P61769; | 100 | 1×NA; 4×GOL; | |||
| Crystal Structure Analysis of NY-ESO-1 epitope, SLLMWITQC, in complex with HLA-A2 |
Heteromer P04439; P61769; | 100 | 1×SO4; | |||
| Crystal structures of high affinity human T-cell receptors bound to pMHC reveal native diagonal bin… |
Heteromer P01848; P04439; P61769; | 100 | 6×SO4; 11×GOL; 1×CA; 1×MG; 1×EPE; | |||
| Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC RevealNative Diagonal Bind… |
Heteromer P01848; P04439; P61769; | 100 | 9×SO4; 3×PGE; 1×7PE; 11×GOL; | |||
| Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances af… |
Heteromer P01848; P01850; P04439; P61769; | 100 | ||||
| Crystal structure of the T-cell receptor NYE_S3 bound to HLA A2*01-SLLMWITQV |
Heteromer P04439; P61769; | 88.89 | ||||
| TCR - CD3 complex bound to HLA |
Heteromer H9BNV4; P01848; P04234; P07766; P09693; P0DTU4; P20963; P61769; | 88.89 | 1×NAG; 8×NAG; 2×CLR; | |||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; P04439; P61769; | 100 | ||||
| Rational development of high-affinity T-cell receptor-like antibodies |
Heteromer P04439; P61769; | 100 | ||||
| Crystal Structure of HLA-A*02:01/NY-ESO-1 (SLLMWITQV) and a target specific TRACeR-I |
Heteromer A0A5B8RNS7; P61769; | 100 | 3×SO4; | |||
| Crystal structure of the T-cell receptor NYE_S1 bound to HLA A2*01-SLLMWITQV |
Heteromer P04439; P61769; | 100 | ||||
| Crystal structure of the T-cell receptor NYE_S2 bound to HLA A2*01-SLLMWITQV |
Heteromer P04439; P61769; | 100 | ||||
| Rational development of high-affinity T-cell receptor-like antibodies |
Heteromer P04439; P61769; | 100 | ||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6gwj.1.A | monomer | 0.75 | 42.25 | |||
1 SWISS-MODEL model built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 6gwj.1.A | monomer | 0.62 | 40.00 | |||